glp-1 obesity news Study: US rates are dropping as use increases World Health Organization recommends GLP-1

CMSs efforts to expand Medicare coverage of GLP-1s for obesity could provide substantial benefits to millions of Medicare beneficiaries, given the potential demand for these highly effective medicationsThere are potential drawbacks to the short-term program, however.

Dipeptidyl peptidase 4 inhibitors are now widely used in the treatment of patients with type 2 diabetes mellitus

Researchers conducted a prospective single-center cohort study of adults with a BMI of 27 kg/m2 or higher using liraglutide (Victoza/Saxenda, Novo Nordisk) or semaglutide (Ozempic/Wegovy, Novo Nordisk)

The memory and focus problems common to depression, researchers hope, may be alleviated by GLP-1 drugs like Wegovy

Consider this post the context-setting for the 2026 Health Populi TrendCast which youll see next week